Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the FDA approval of moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.
Javier A. Pinilla-Ibarz, MD, PhD
Advertisement
Articles by Javier A. Pinilla-Ibarz, MD, PhD
Advertisement
Latest Updated Articles
Dr. Pinilla-Ibarz on the FDA Approval of Moxetumomab Pasudotox in Hairy Cell LeukemiaPublished: September 13th 2018 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Naji Gehchan, MD, MBA, on Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis
2
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
3
Quarter Century Update: Future Predictions for the Field
4
Quarter Century Update: What Does the Field Need Most Right Now?
5
